Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q1 FY19 results · Apr–Jun 2018
Bliss GVS Pharma reported revenue from operations of ₹205.33 crore and net profit of ₹38.98 crore for Q1 FY19 (Apr–Jun 2018), on a consolidated basis.
| Item | Q1 FY19 | Q1 FY18 | YoY | Q4 FY18 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 205.33 | — | — | — | — |
| Other income | 13.87 | — | — | — | — |
| Total income | 219.20 | — | — | — | — |
| Profit before tax | 51.04 | — | — | — | — |
| Net profit for the period | 38.98 | — | — | — | — |
| Attributable to shareholders of the company | 38.32 | — | — | — | — |
| EPS, basic (₹) | 3.72 | — | — | — | — |
| Net margin (%) | 19.0 | — | — |
| Item | Q1 FY19 | Q1 FY18 | YoY | Q4 FY18 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 104.84 | — | — | — | — |
| Other income | 13.14 | — | — | — | — |
| Total income | 117.98 | — | — | — | — |
| Profit before tax | 37.68 | — | — | — | — |
| Net profit for the period | 27.05 | — | — | — | — |
| EPS, basic (₹) | 2.62 | — | — | — | — |
| Net margin (%) | 25.8 | — | — |
Consolidated
- Filed with BSE
- 13 Aug 2018, 15:01 IST
- Board meeting
- 09 Aug 2018
- Period
- 01 Apr 2018 to 30 Jun 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Aug 2018, 15:01 IST
- Board meeting
- 09 Aug 2018
- Period
- 01 Apr 2018 to 30 Jun 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE